WinstonWınston
Airway Medix S.A. logo

Airway Medix S.A.

AWM.WA
26
Medical - Instruments & Supplies · Healthcare
Price
0.27 PLN
-0.00 (-0.56%)
Market Cap
30.8M PLN
Exchange
Warsaw Stock Exchange
Winston Score
26
Winston is worried
Below-average fundamentals — multiple weak pillars.
Data as of Aug 9, 2026 · filings through Mar 31, 2026

Share count rising — dilution

+59.8% over 4y

The company has issued more shares over this period, which dilutes each existing shareholder’s stake.

Diluted shares outstanding: 58.4M (2021) → 93.3M (2025)

Airway Medix S.A. is a Polish medical device company that makes specialized tools for managing patients' airways in hospitals. Its main product is a closed suction catheter system designed to help clear mucus from the lungs of patients on ventilators, particularly in intensive care units. The company sells primarily to hospitals and healthcare facilities, competing in the niche market for airway management supplies.

The company earns revenue by selling its medical devices directly to hospitals and through distributors, mainly in Europe. It is a very small company, with a market cap near zero and deeply negative profit margins, meaning it currently spends far more than it earns. Airway Medix is still in an early commercial stage, which explains the extreme losses shown in its financials. The key risk is whether the company can scale sales fast enough to reach profitability before it runs out of funding, as it remains heavily dependent on outside capital to continue operating.

Winston Score History

Growth Profile

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

YoY Growth Rate

Revenue data limited

EPS Growth

+7.6% YoY

YoY Growth Rate

Slow EPS growth

R&D Spend

$0/ year

0.0% of revenue

Below sector average (18%)

Research and development spending

Insider Activity

77.5%ownership

Insiders own a meaningful stake in the company

Cash Position

Cash flow positive

$441,000 cash & investments

Quarterly Free Cash Flow

Company generates more cash than it spends — no dilution risk from fundraising

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Gross Margin
-822.4%
Thin — -822.4% gross margin
Operating Margin
-1004.7%
Losing money on operations — -1004.7%
ROCE
-27.5%
Weak — -27.5% return on capital

Negative ROIC means the business is losing money on every dollar invested in it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales YoY
+641.7%
Fast-growing sales (+641.7% YoY)
EPS YoY
N/A
Data not available
EPS Consistency
5/8 quarters
Mixed — about half the quarters showed growth

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Cash Conversion
-77%
Weak — only -77% of profit becomes cash
FCF Margin
-1437.1%
Burning cash (-1437.1%)

Free cash flow is negative. They are burning cash, not generating it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

Debt / Equity
N/A
Data not available
Interest Cover
N/A
Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

P/E Ratio (TTM)
17.5x
Fair value — P/E 17.5

P/E in the normal range. Price is roughly $15 for every $1 of yearly profit.

P/E vs Forward
N/A
not available
Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Not applicable for this business.
🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.
Start free trial